Research & Development
FDA approves Merck's Keytruda combinations for first-line treatment of PD-L1-positive advanced triple-negative breast cancer
25 June 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that the US Food and Drug Administration (FDA) has approved Keytru...
Ionis licenses ex-US rights to zilganersen for Alexander disease to Recordati
25 June 2026 - Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) said on Thursday that it has entered into a licensing agreement granting Recordati exclusive rights to develop and commerci...
Dicot Pharma receives FDA clearance to start Phase 2b study of LIB-01 in US
25 June 2026 - Swedish pharmaceutical company Dicot Pharma AB (Nasdaq First North:DICOT) said on Thursday that it has received clearance from the US Food and Drug Administration (FDA) to initiate Part...
CeleCor Therapeutics submits final section of zalunfiban (Disaggpro) New Drug Application to US FDA
25 June 2026 - US pharmaceutical company CeleCor Therapeutics said on Wednesday that it has submitted the final section of its New Drug Application (NDA) for the company's investigational heart-a...
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead...
ZETA SURGICAL reports first patient treated with Zeta TMS Navigation System at HOPE Therapeutics
24 June 2026 - Medical technology manufacturer ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq:NRXP), announced on Tuesday that the first patient has been treated with the ...